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Abstract: 
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental 
disorder affecting approximately 5% of children. Although a wealth of evidence shows a 
significant genetic component to the disease, definitive genetic mechanisms have not 
been identified. Pathway analyses, a subset of gene-set analyses, are methods to extend 
the knowledge gained from genome-wide association studies (GWAS) by providing 
functional context for genetic associations. However, a key issue is that there are 
numerous methods for association testing of gene sets and no real consensus regarding 
the best approach. The present study applied six pathway analysis methods to identify 
biological pathways associated with ADHD in two GWAS datasets from the Psychiatric 
Genomics Consortium. Each of these methods uses a different technique for aggregating 
individual SNP-level effects to produce a pathway-level association measure. Methods 
that utilize genotypes to model pathway-level effects were found to identify more 
replicable pathway associations than methods using summary statistics. In addition, 
pathways implicated by more than one analysis method were more likely to replicate. A 
consensus of results across methods was determined by using a simple voting scheme, 
and by calculating the median p-value. Pathways containing potassium channel genes 
and others involved in RhoA signaling, glycosaminoglycan biosynthesis, and fibroblast 
growth factor receptor activity were nominally significant by multiple methods in two 
independent datasets. These results support previous hypotheses about the role of 
regulation of neurotransmitter release, neurite outgrowth and axon guidance in 
 7 
contributing to the ADHD phenotype and suggest the value of cross-method 
convergence in evaluating pathway analysis results. 
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Introduction 
Attention deficit hyperactivity disorder (ADHD) is a common and heritable 
neurodevelopmental disorder that affects approximately 5% of children worldwide. The 
disorder is characterized by symptoms of inattention, hyperactivity, and impulsivity, and 
frequently persists in impairing form into adulthood [1].  
While the heritability of ADHD has been estimated to be 60-80% [2], definitive 
genetic mechanisms have not yet been identified. Meta-analyses of candidate gene 
studies have identified genes consistently associated with ADHD (DAT1, DRD4, DRD5, 5-
HTT, HTR1B, SNAP25), although collectively these account for less than 5% of genetic 
variance in ADHD and none are diagnostic. Unsurprisingly, such studies have also 
highlighted the genetic heterogeneity among ADHD patients [2-6].  
Genome-wide association studies (GWAS) [7-19] have revealed additional candidate 
genes (e.g. CDH13, SPOCK3, KCNC1, KCNIP1, KCNIP4), although these variants have not 
achieved genome-wide significance [13,18,20,21]. The most consistent finding is the 
CDH13 gene, which has been implicated in two family-based GWAS [7,8] and two case-
control GWAS [10,12]. Results from studies of other neuropsychiatric disorders [22] 
suggest that studies with tens of thousands of subjects will likely be needed to reveal 
more definitive single variant associations.  
Gene set methods, which test for association between groups of genes and a trait, 
offer a means of extending and contextualizing the knowledge gained from GWAS for 
several reasons. First, ADHD, like other complex diseases, is polygenic in nature, so 
testing for association with sets of related variants (e.g. those influencing a biochemical 
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pathway) can provide a functional context for multiple genetic risk factors and 
potentially yield new mechanisms and treatment targets.  
Second, because the number of gene sets is far fewer than the number of SNPs in a 
GWAS, examining gene sets improves power to detect genetic correlates by reducing 
the multiple testing correction. A third advantage is that effects due to genetic 
heterogeneity can be detected. This is related to the issue of small effect sizes, since the 
result of genetic heterogeneity in a study population will be a mixture of small-effect 
variants. If multiple small effects are present within a pathway it may be possible to 
detect their cumulative effect using pathway analysis methods.  
ADHD is an ideal candidate for pathway analysis given the evidence supporting a 
polygenic model of disease susceptibility [16,23-25]. A few pathway analyses, using a 
variety of pathway definitions and statistical methods, have been conducted on ADHD 
datasets. Poelmans et al. identified the top 85 genes reported in five ADHD GWAS and 
performed a literature search for gene functions. They reported that 45 of the 85 GWAS 
hits could be assigned to a neurodevelopment network involved in directed neurite 
outgrowth [26]. Similarly, Cristino et al. found that ADHD-associated genes are 
significantly more interconnected in a protein-protein interaction network than 
expected by chance [27]. 
Stergiakouli et al. performed a pathway analysis on an ADHD GWAS dataset 
consisting of 727 children with ADHD and 5081 controls. Using the ALIGATOR method 
they found that 13 significant pathways also contained an excess of CNV-affected genes. 
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Pathways related to cholesterol metabolism, cation channel activity, and CNS 
development were implicated [14].  
Yang et al. applied three analysis methods, INRICH [28], DAPPLE [29], and GREAT 
[30], to a GWAS dataset consisting of 1400 cases and 963 controls of Chinese descent. 
Although results from the three methods differed somewhat, common processes, such 
as cell adhesion, glutamate synaptic development, and axon development, were 
implicated [16] 
Bralten et al. performed a candidate pathway analysis using data from the 
International Multi-site ADHD Genetics (IMAGE) study [7], consisting of 909 trios. Three 
candidate gene sets (dopamine/norepinephrine pathway, serotonin pathway, and 
neuritic outgrowth pathway) were defined using the Ingenuity software 
(www.ingenuity.com) and a literature review. The three pathways combined were 
associated with hyperactive/impulsive symptomatology but not inattention 
symptomatology [31].  
Hammerschlag et al. tested 17 expert-curated gene sets of pre- and post-synaptic 
genes in the IMAGE2 case-control dataset, which consists of 896 cases and 2455 
controls [12]. However, none were more strongly associated with ADHD than random 
gene sets of equal size [32].  
The results from these previous gene set analyses performed on ADHD datasets 
provide further evidence of the polygenic nature of the disorder. However, they also 
underscore the challenge of interpreting pathway analyses due to the variation among 
methods. This challenge is substantial because of the large number of ways to define a 
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gene set and to test for association between a gene set and a phenotype [33]. This issue 
is highlighted in the recent study by O’Dushlaine et al. that examined gene set (a 
mixture of Gene Ontology and pathway models) enrichment across five different 
methods to rank pathways associated with schizophrenia, major depression and bipolar 
disorder [34].  
The present study is unlike prior pathway analyses in ADHD, in that it focuses on 
methods that use genotypes (rather than summary statistics) to model gene- or 
pathway-level association measures. Our main hypothesis was that methods utilizing 
genotypes would better represent the underlying genetic architecture and therefore 
would identify more replicable pathway associations. We applied four such methods, 
and compared them with two commonly used methods that rely on summary statistics.  
Because of the different results expected from different pathway analysis 
algorithms, we aimed to discover robust pathway-level effects by identifying a 
consensus of pathway significance across the methods and multiple independent data 
sets. Our second hypothesis was that this ensemble approach for identifying robust 
pathway effects would confirm prior findings that neuro-developmental processes are 
important genetic mechanisms in ADHD.  
 
Data & Methods 
Participants and Genotype Data 
Two independent, ADHD case-control, GWAS datasets from the Psychiatric 
Genomics Consortium, which will be referred to as the (a) IMAGE2 (N=3351; mean age = 
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10.5, SD = 2.9) and (b) German ADHD GWAS (N=1793; mean age = 11, SD = 2.7) datasets, 
were used for our analysis [12,13]. Details about these datasets and the genotype 
QA/QC procedures are available in the Supplementary Methods.  
 
Gene Sets 
The pathways tested were obtained from the Pathway Commons database 
(www.pathwaycommons.org; version 4) [35], which included a total of 3074 human 
pathways from the following sources: Reactome (www.reactome.org; v46) [36], NCI 
Pathway Interaction Database (pid.nci.nih.gov; 16-AUG-2012) [37], HumanCyc 
(humancyc.org; 17.1) [38], and PANTHER (www.pantherdb.org/pathway/; 3.2.1) [39]. 
This initial collection of pathways was filtered by removing those with only a single gene, 
those with more than 300 genes, and duplicates (same name and same genes). If two 
pathways shared the same name, but contained different members, the gene members 
were merged to create a single pathway. Uniprot IDs were converted to Ensemble gene 
IDs using the mapping contained in the Ensembl database (version 74). The final set of 
2233 pathways ranged in size from 2 to 284 genes (mean=31, SD=39). Because of the 
different requirements of each analysis method, very small pathways were not tested by 
all methods. Of the final set of 2233 pathways, 1980 and 2057 were tested by all 
methods in the IMAGE2 and German ADHD GWAS datasets, respectively. Figure 1 
provides an overview of our pathway analysis workflow. 
 
Mapping SNPs to Genes 
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SNPs were mapped to pathway genes if located within 1Kb of the gene boundaries. 
Gene and SNP locations were obtained from the Ensembl database (www.ensembl.org; 
v74). For the IMAGE2 dataset, 52921 SNPs were mapped to 5093 pathway genes. For 
the German ADHD GWAS dataset, 103128 SNPs were mapped to 6136 pathway genes.  
 
Pathway Analysis Methods 
Six pathway analysis methods were applied to both datasets. Four were previously 
published methods that use the original genotype data rather than SNP p-values: 
GRASS, PCgamma, PoDA, and NBF [40-43]. Two were previously published methods that 
utilize SNP p-values: GSEA [44] and Fisher's method for combining p-values [43,45]. See 
the supplementary methods for more details on these algorithms. To examine the 
individual SNP effects contributing to pathway associations, SNP-level p-values were 
calculated using the logistic regression procedure in Plink v1.07 [46]. 
 
Adjustment for Pathway Size 
Although often overlooked, an obvious confound in interpreting pathway analysis 
results is that pathways with more SNPs ("larger" pathways) are more likely to be 
associated with the phenotype [33,44,47,48]. The degree of correlation between 
pathway size and pathway significance was therefore examined for all methods. When a 
significant correlation was seen, pathway p-values were adjusted as follows.  
For each pathway, a collection of random pathways was constructed in order to 
calculate a null distribution of p-values. These random pathways were created to 
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approximately match the number of genes and SNPs in the target pathway. This was 
accomplished by binning all genes according to the number of SNPs assigned to each 
gene. Because genes with a large number of SNPs are rare, bins were merged so that 
each contained approximately 25 genes. Random pathways were then created by 
sampling the appropriate number of genes from each bin. The adjusted p-value is simply 
the proportion of random pathways with a p-value smaller than the p-value of the 
target pathway. 
 
Results 
Accounting for Pathway Size 
We first considered the effect of pathway size in the IMAGE2 data set. Both the 
PoDA and GSEA methods have built-in permutation procedures that successfully 
corrected for size bias (correlation p-values > 0.2). The four other methods all had 
significant correlations between pathway size and significance of association to ADHD. 
These effects were small for PCgamma and GRASS (Pearson's correlation coefficients, r, 
of 0.169 and 0.068, respectively; p-values < 0.002). However, the results from Fisher's 
method were highly correlated with pathway size (r = 0.95, p-value < 2  10-16). In 
addition, there was a significant negative correlation between pathway size and 
pathway significance (the inverse of the Bayes Factor) reported by the NBF method (r = -
0.40, p-value < 2  10-16).  
Therefore, p-values from the PCgamma, GRASS, and Fisher's methods were adjusted 
for pathway size as described in Methods. This procedure successfully corrected the size 
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bias for PCgamma and Fisher's methods (correlation p-values > 0.13), but 
"overcorrected" and resulted in a slight negative correlation between size and 
significance for GRASS (r = -0.045, p-value = 0.036) (Supplementary Figure 1). However, 
the adjusted p-value was retained. The results from the NBF method could not be 
corrected because the hierarchical model used in that method does not allow for the 
application of permutation-based correction. 
In the German ADHD GWAS dataset, we repeated these checks. Similar results 
regarding the relationship between pathway size and significance were seen (data not 
shown), and therefore corrections were applied in the same way. All pathway p-values 
reported below are adjusted for pathway size either inherently or by our permutation 
procedure. All pathway-level association statistics (both adjusted and unadjusted) and 
the number of genes and SNPs in each pathway are reported in Supplementary Tables 
1-4. 
 
Comparing Pathway Analysis Algorithms 
A total of 1980 pathways were tested by all methods in the IMAGE2 dataset; the 
number of pathways reported as nominally significant ranged from 88 for GSEA to 61 for 
the NBF method. Pathways reported as nominally significant by Fisher's, PCgamma , and 
GRASS were most likely to also be significant by at least one other method (74.6%, 
74.1%, and 62.9%, respectively), while those reported as nominally significant by NBF 
were least likely to be confirmed by a second method (22.9%) (Table 1).  
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This initial finding replicated well in the German ADHD GWAS dataset, with the 
PCgamma, GRASS, and Fisher's methods overlapping most with other methods (74%, 
72.5%, and 72.2%, respectively) and the NBF method overlapping the least (25%). 
With regard to cross-sample replication of particular pathways associated with 
ADHD, PCgamma had the highest proportion of nominally significant pathways that 
were also reported as nominally significant in the German ADHD GWAS dataset (16.8%), 
followed by GRASS and PoDA (~12%). GSEA, Fisher's Method, and the NBF method all 
had replication rates below 9% (Table 1). This finding is consistent with our hypothesis 
that methods utilizing genotypes would identify more replicable associations, the NBF 
method being an exception. The small sample size of each data set is a limitation of our 
study and is likely responsible, in part, for the discordance between results in the two 
datasets. 
Next, for each pathway, p-values from both cohorts were combined, using Fisher's 
method [45], to create a single pooled p-value for each analysis method except NBF 
(which reports a Bayes factor, not a p-value). The number of methods reporting a 
pooled p-value ≤ 0.05 was counted and the median pooled p-value for each pathway 
was calculated. Table 2 shows the top 25 most significant pathways ranked by median 
pooled p-value. The most significant pathway by any method was the Potassium 
Channels pathway, with a pooled size-adjusted p-value of 4.11  10-5 for the GRASS 
algorithm. 
Given the limited amount of overlap seen among the different methods, discordant 
pathways were examined in order to gain a better understanding of the differences 
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between methods. We use the term "discordant pathway" to mean one that is reported 
as significant by only a single method (9.3% of pathways tested by all methods).  
We hypothesize that differences in the distribution of SNP-level p-values among 
pathways may explain some of the discordance across methods. For instance, some 
methods may be more sensitive to pathways containing a few strong to moderate SNP 
effects, while others are more sensitive to pathways with many small SNP effects.  
To examine differences in genetic effects for discordant pathways, SNP-level p-
values were calculated using the logistic regression procedure in Plink v1.07 [46]. Next, 
each gene was assigned the minimum p-value among all SNPs in that gene. The 
distribution of the minimum gene-level p-value and the median gene-level p-value for 
each method's discordant pathways are plotted in Supplementary Figures 2 and 3. 
These plots show that gene-level effects within pathways implicated by one method are, 
in some cases, significantly different from the gene-level effects within pathways 
implicated by another method. For example, pathways reported as significant by only 
PCgamma tend to have a smaller minimum gene-level p-value compared to pathways 
reported as significant by only GSEA (t-test p-value < 0.0005 for both IMAGE2 and 
German ADHD GWAS datasets). This suggests that PCgamma is sensitive to pathways 
with only a few moderate SNP effects, while GSEA is sensitive to pathways with many 
small effects.  
These observations support previous assertions [34,49] that it may be beneficial to 
apply multiple analysis methods to a dataset, since the results from different methods 
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can be complementary. Furthermore, it is likely that pathways reported as significant by 
multiple methods are more stable and replicable (not due to spurious genetic effects).  
For example, 46 pathways were reported as nominally significant by three or more 
methods in the IMAGE2 data set, while 211 pathways were nominally significant by only 
a single method. A significantly higher proportion of the pathways identified by three or 
more methods replicated in the German ADHD GWAS dataset (16 of 46; 34%), 
compared to the pathways identified by only a single method (35 of 211; 17%) (Fisher's 
exact test p-value = 0.0078).  
Seven pathways were reported nominally significant by more than one method in 
both cohorts (pathways bold in Table 2). Q-Q plots of SNP-level p-values for all SNPs in 
each of these pathways show an excess of weak effects (Figure 2). These observations 
are consistent with a polygenic model of disease risk for ADHD, as has been 
demonstrated previously [16,23-25,50]. 
Supplemental analyses were done to evaluate the use of imputed genotypes for 
pathway analysis (Supplementary Tables 5 and 6). 
 
Specific Pathway Findings for ADHD 
Pathways reported as nominally significant by at least two methods in both data sets 
are: Ca activated K+ channels, FGFR1b ligand binding and activation, FGFR2b ligand 
binding and activation, Potassium Channels, Validated targets of C-MYC transcriptional 
repression, RhoA signaling pathway, and Chondroitin sulfate biosynthesis. All of these 
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are expressed in the brain and are relevant to neuro-development. Here we present 
biological context for these pathways and supporting evidence for their role in ADHD.  
Potassium channel genes have been implicated in a number of previous GWAS and 
pathway analyses of ADHD [7,8,10,16,20]. These findings from genetic studies are 
supported by research on the role of potassium channels in the regulation of 
dopaminergic neurons [51]. For instance, Fulton et al. found that a Kv1 channel blocker 
significantly increased dopamine release in mouse midbrain dopamine neurons, and 
provided evidence that the D2 dopamine autoreceptor attenuates dopamine release 
through regulation of Kv1 voltage-gated potassium channels [52]. 
Pharmacological studies provide additional support for the role of potassium 
channels in ADHD. Kobayashi et al. found that atomoxetine, a norepinephrine reuptake 
inhibitor approved for the treatment of ADHD, significantly reduced inward currents 
through G-protein-activated inwardly rectifying K+ (GIRK) channels expressed in 
Xenopus oocytes [53]. And Sasaki et al. conducted a preliminary study on the efficacy of 
tipepidine, reported to inhibit GIRK channel currents [54], to treat childhood ADHD. 
They found that ADHD Rating Scale IV scores improved significantly for 10 ADHD 
patients after taking 30mg of tipepidine daily for 4 weeks [55].  
Figure 3 shows gene-level association measures (minimum SNP p-value) for all 
potassium channel genes, along with interactions from the STRING protein-protein 
interaction database (low-confidence interactions excluded) [56]. Also plotted are the 
distributions of distance scores, S, (as calculated by the PoDA algorithm) showing a 
significant difference between cases and controls (odds ratios of 1.41 and 1.81 for the 
 20 
IMAGE2 and German ADHD GWAS study groups, respectively; FDR adjusted p-values < 3 
 10-13).  
One hypothesis regarding the etiology of ADHD involves a dysregulation of 
developmental processes, particularly axon guidance and neurite outgrowth [26,57]. A 
number of the pathways implicated in this study contribute to these neuro-
developmental processes, namely the RhoA signaling pathway, pathways involved in 
proteoglycan metabolism, and pathways involved in fibroblast growth factor receptor 
activation. Although the role of c-Myc in neurodevelopment has not been studied 
extensively [58], c-Myc knockout models show significant effects on brain growth [59], 
and the interaction between c-Myc and RhoA in cancer is well known [60]. 
A recent review by Stankiewicz and others summarizes the abundance of literature 
describing the role of Rho family GTPases in neurodevelopment [61]. RhoA in particular 
has been shown to regulate neuronal survival and migration during development [62-
64]. Note that 14 of 45 genes (31%) in the RhoA signaling pathway are also members of 
the much larger axon guidance pathway (280 genes).  
Chondroitin sulfate proteoglycans (CSPGs) are thought to act as inhibitory signals to 
guide neuronal growth [65,66]. It has been proposed that the inhibitory effect of the 
Rho/ROCK pathway on neurite growth is mediated by CSPGs [67,68]. Monnier et al. 
demonstrated that both an inhibitor of Rho and an inhibitor of the ROCK kinase were 
able to block CSPG inhibition of axon growth [67]. Siebert et al. confirmed this finding 
and further showed that chondroitinase ABC, which removes the glycosaminoglycan 
chains from CSPGs, counteracts the inhibition of axon growth [66].  
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Interestingly, the SPOCK3 gene, which encodes a calcium-binding proteoglycan 
expressed in the brain, has previously been implicated in GWAS of ADHD and 
personality disorders [7,17]. 
Like CSPGs, heparan sulfate proteoglycans (HSPGs) have been shown to play a role in 
axon guidance and neuronal growth [69,70]. HSPGs may exert their effect through the 
activation of fibroblast growth factor receptor (FGFR) signaling pathways [71], which are 
important in neurite outgrowth [72,73] and other neuronal development processes [74]. 
It has also been suggested that FGRFs may interact with the ADHD-susceptibility gene 
CDH13 [57].  
 
Discussion 
An abundance of data on the genetics of ADHD has been produced in recent years. 
Although results have been inconsistent, patterns are beginning to emerge. First, 
multiple studies have demonstrated the polygenic nature of the disorder [16,23-25]. The 
observation that ADHD is likely due to the cumulative effect of many genes, each 
contributing only a small effect on their own, explains much of the discordance among 
previous genetic association studies, which have largely been underpowered to detect 
small effects. 
The predictive value of polygenic risk scores provides hope that larger studies will be 
able to produce more definitive genetic associations [50]. Furthermore, when taking a 
higher-level view of the reported genetic associations, a number of cellular processes 
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have consistently been implicated. For instance, genes involved in cell-cell signaling, 
adhesion, and neural development have been top hits in multiple studies.  
Gaining insights by taking this process-level view is precisely the goal of pathway 
analyses. Given the variety of algorithms for aggregating SNP-level effects, we aimed to 
combine the results from multiple analysis methods to identify pathways most likely 
associated with ADHD. We identified seven pathways reported as nominally significant 
by multiple analysis methods in two independent data sets (Table 2). Each of these 
pathways was found to contain an excess of small SNP effects consistent with a 
polygenic model of disease risk. Furthermore, these pathways provide additional 
support for previous hypotheses about the etiology of ADHD, particularly related to the 
regulation of neurotransmitter release, and neuro-developmental processes.  
Methods that test for the cumulative effect of multiple genes increase the strength 
of secondary analyses, and allow researchers to extract additional information from 
currently available datasets. Our results and others [26] have shown the ability to place 
individual genetic associations within a meaningful biological context that will help focus 
future research and guide the development of hypotheses about the mechanisms of 
ADHD susceptibility. 
 
Supplementary information is available at Molecular Psychiatry’s website. 
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Tables 
Table 1. Number of Nominally Significant Pathways in the IMAGE2 Dataset 
Method 
Proportion of nominally 
significant pathways  
(p ≤ 0.05) confirmed in at 
least one other method* 
Proportion of nominally 
significant pathways  
(p ≤ 0.05) confirmed in the 
German ADHD GWAS 
dataset 
PCgamma 63 / 85 (74.1 %) 15 / 89 (16.8 %) 
GRASS 39 / 62 (62.9 %) 8 / 65 (12.3 %) 
PoDA 46 / 75 (61.3 %) 9 / 75 (12 %) 
GSEA 45 / 88 (51.1 %) 8 / 93 (8.6 %) 
FM 59 / 79 (74.6 %) 5 / 83 (6.0 %) 
NBF 14 / 61 (22.9 %) 1 / 84 (1.1 %) 
* Denominators in this column are slightly smaller because they reflect only those 
pathways tested by all methods. Here we refer to a pathway as confirmed in two 
different ways: 1) when it is nominally significant (p ≤ 0.05) by a second analysis method 
in the IMAGE2 dataset (center column); or 2) when it is nominally significant using the 
same analysis method in an independent dataset (the German ADHD GWAS dataset; 
right column). 
 
Table 2. Top 25 Most Significant Pathways 
Pathway Pathway Size  
(SNP Count) 
IMAGE2 / 
German 
ADHD GWAS 
Methods 
with 
Nominal 
Significance 
Median  
Pooled 
P-value 
Ca activated K+ channels * 262 / 487 5 0.0010 
FGFR1b ligand binding and activation 56 / 126 5 0.0011 
FGFR2b ligand binding and activation 64 / 145 5 0.0023 
Potassium Channels 1065 / 2117 4 0.0026 
Signaling mediated by p38-gamma and p38-
delta 58 / 108 4 0.0043 
Validated targets of C-MYC transcriptional 
repression * 243 / 548 5 0.0060 
 41 
RhoA signaling pathway 295 / 507 4 0.0075 
tnf/stress related signaling 111 / 217 5 0.0089 
histidine degradation III * 41 / 79 3 0.0113 
Dermatan sulfate biosynthesis 85 / 206 4 0.0116 
Chondroitin sulfate biosynthesis 219 / 451 4 0.0157 
Metabolism of Angiotensinogen to 
Angiotensins * 70 / 143 3 0.0160 
Clearance of Nuclear Envelope Membranes 
from Chromatin * 39 / 83 4 0.0165 
Histidine catabolism * 21 / 52 4 0.0184 
Translesion synthesis by DNA polymerases 
bypassing lesion on DNA template * 11 / 13 4 0.0189 
FGFR1 ligand binding and activation 69 / 166 5 0.0197 
RAC1 signaling pathway 282 / 446 4 0.0197 
Regulation of signaling by CBL 180 / 322 3 0.0224 
Caspase-mediated cleavage of cytoskeletal 
proteins 128 / 208 4 0.0238 
FGFR2 ligand binding and activation 81 / 201 4 0.0240 
DNA Damage Bypass * 11 / 13 3 0.0254 
human cytomegalovirus and map kinase 
pathways 69 / 143 3 0.0295 
Rapoport-Luebering glycolytic shunt 5 / 12 3 0.0298 
Thromboxane A2 receptor signaling * 821 / 1586 3 0.0299 
LKB1 signaling events 305 / 482 3 0.0304 
Pathways in bold were reported nominally significant by multiple methods in both the 
IMAGE2 and German ADHD GWAS datasets. Pathways marked with an * were also 
nominally significant by at least one method in the post-imputation analysis 
(Supplementary Tables 1 and 2). For each pathway the following information is 
provided: the number of SNPs assigned to the pathway in each data set, the number of 
analysis methods reporting the pathway nominally significant, and the median pooled p-
value across all the analysis methods.   
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Figures 
Figure 1. Pathway analysis workflow. Pathways tested were retrieved from the Pathway 
Commons database. Genotyped (and imputed) SNPs were mapped to genes in the 
pathways, and six pathway analysis algorithms were used to test for association with 
ADHD. A random pathway permutation procedure was used to adjust pathway 
significance for pathway size. Finally, pathways were ranked based on the number of 
methods reporting significance and the median p-value across methods. 
 
Figure 2. Q-Q plots for seven pathways found nominally significant in both cohorts. Each 
pathway shows an excess of small SNP effects consistent with a polygenic model of 
disease risk. 
 
Figure 3. A) The Potassium Channels pathway genes overlaid onto the STRING protein-
protein interaction network (low confidence interactions, STRING score < 0.5, were 
removed). Node size is proportion to the IMAGE2 gene p-value, while label size is 
proportional to the German ADHD GWAS gene p-value. Green node border indicates a 
gene p-value <= 0.05 in the IMAGE2 dataset, and a green label indicates the same in the 
German ADHD GWAS dataset. Gray border or label indicates no SNPs present in a 
particular gene. B) and C) Pathway of Distinction Analysis (PoDA) S scores showing a 
difference in the distribution between cases and controls in both the IMAGE2 and 
German ADHD GWAS datasets, respectively. 
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Supplementary Figure 1. The relationship between gene set association significance and 
the number of SNPs assigned to the gene set. The gene set size bias affects the applied 
methods to varying degrees. After correction the comparability of results from different 
methods is greatly improved.  
 
Supplementary Figure 2. Density plots showing the distribution of gene-level p-values 
across pathways reported as nominally significant by only one method in the IMAGE2 
dataset. The differences among the p-value distributions for each method suggest the 
methods are sensitive to different types of pathway-level genetic effects (i.e. different 
compositions of individual SNP effects). 
 
Supplementary Figure 3. Density plots showing the distribution of gene-level p-values 
across pathways reported as nominally significant by only one method in the German 
ADHD GWAS dataset. 
